Altimmune, Inc. ALT | NASDAQ
|2026-09-25
|F&G 43
|RSI 35.7
Company Overview:
9.3 Year ALT Performance Metrics:
ALT Dividend Charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
ALT Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
ALT Dividends Info:
ALT Dividend History: Dates, Payments & Yield list
Below is a schedule of all ALT dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield
| Ex-Date | Payment Date | Amount | Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 01/20/2017 | 02/03/2017 | $873.010 | 0% | 0% | $- |
| 02/06/2017 | 11/30/-0001 | $873.000 | 0% | 0% | $- |
Projected Future Returns & Dividends for ALT
Based on past 9.3-year performance, here are ALT growth metrics:
Share price CAGR of -34.04%
Dividend CAGR of +0%
Using ALT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ALT (DRIP) | ALT - No DRIP | |
|---|---|---|
| Current Price | $2.78 | $2.78 |
| Start Shares | 3,597.12 | 3,597.12 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,000,000.00 | 3,597.12 |
| Dividends Payment | $250.57 | $250.57 |
| Annual Dividends | $3,006,884,717 | $10,816,132 |
| Yield on cost | 30,068,847.17% | 108,161.32% |
| Share Price | $0.80 | $0.80 |
| Total Dividends | $21,075,082,071 | $78,938,675 |
| Final Value | $797,923 | $78,941,546 |
NOTE: Above numbers are our estimate based on ALT's Dividend and Price CAGR over past 9.3 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Company Info
Altimmune, Inc. (ALT) had its IPO on 2017-05-26, and is traded on NASDAQ stock exchange.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT website: https://altimmune.com
Get Full Access to All Reports with DRIPCalc PRO
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
DCF Model — ALT
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
